PD-1 antibody

Catalog No. ABIN7566443

The Mouse Monoclonal anti-PD-1 antibody has been validated for IHC and ELISA. It is suitable to detect PD-1 in samples from Human.

Quick Overview for PD-1 antibody (ABIN7566443)

Target: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This PD-1 antibody is un-conjugated

Application: Immunohistochemistry (IHC), ELISA

Clone: AG-IHC001

Product Details anti-PD-1 Antibody

Purpose: anti-PD-1 (human), mAb (AG-IHC001)

Characteristics:

Monoclonal Antibody. Recognizes human PD-1 (CD279). Applications: ELISA, IHC. Isotype: Mouse IgG2b. Clone: AG-IHC001. Liquid. In Tris Buffer, pH 7.4, containing 1 % BSA and <0.1 % sodium azide. Programmed Death 1 (PD-1) is a member of the CD28/CTLA-4 family of T cell regulators, expressed as a co-receptor on the surface of activated T cells, B cells and macrophages. Several studies have suggested that the PD-1/PD-L1 signaling pathway may be linked to antitumor immunity, as PD-L1 has been shown to induce apoptosis of activated T cells or inhibit activity of cytotoxic T cells. In comparison to CD10 and Bcl-6, PD-1 is expressed by fewer B cells and has therefore been considered a more specific and useful diagnostic marker for angioimmunoblastic T cell lymphoma. Therapies targeted toward the PD-1 receptor have shown remarkable clinical responses in patients with various types of cancer, including non-small-cell lung cancer, melanoma and renal-cell cancer. This antibody is intended to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed, paraffin-embedded tissue sections using IHC test methods. It has been optimized and validated using the BOND-MAX fully automated IHC&ISH stainer (see Protocol).

Programmed Death 1 (PD-1) is a member of the CD28/CTLA-4 family of T cell regulators, expressed as a co-receptor on the surface of activated T cells, B cells and macrophages. Several studies have suggested that the PD-1/PD-L1 signaling pathway may be linked to antitumor immunity, as PD-L1 has been shown to induce apoptosis of activated T cells or inhibit activity of cytotoxic T cells. In comparison to CD10 and Bcl-6, PD-1 is expressed by fewer B cells and has therefore been considered a more specific and useful diagnostic marker for angioimmunoblastic T cell lymphoma. Therapies targeted toward the PD-1 receptor have shown remarkable clinical responses in patients with various types of cancer, including non-small-cell lung cancer, melanoma and renal-cell cancer. This antibody is intended to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed, paraffin-embedded tissue sections using IHC test methods. It has been optimized and validated using the BOND-MAX fully automated IHC&ISH stainer (see Protocol).

Purification: Protein A/G purified.

Immunogen: Recombinant human PD-1 fused to a His-tag.

Isotype: IgG2b

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: In Tris Buffer, pH 7.4, containing 1 % BSA and <0.1 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Do not freeze.

Storage: 4 °C

Storage Comment:

Stable for at least 1 year after receipt when stored at +4°C.

Target Details for PD-1

Target: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Alternative Name: PD-1

UniProt: Q15116

Pathways: Cancer Immune Checkpoints